Less Ads, More Data, More Tools Register for FREE

Pin to quick pickspolarean Regulatory News (POLX)

  • There is currently no data for POLX

Director Dealing

22 Jan 2020 16:03

RNS Number : 6364A
Polarean Imaging PLC
22 January 2020
 

Polarean Imaging Plc 

("Polarean" or the "Company")

 

Director Dealing

 

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that yesterday it was notified that Dr Jonathan Allis, a Non-Executive Director of the Company, purchased 337,574 Ordinary Shares of £0.00037 ("Ordinary Shares") at an average price of 29.6 pence per share on 20 January 2020.

Following this transaction, Dr Allis now holds a beneficial interest in 1,877,574 Ordinary Shares, representing approximately 1.64 per cent. of the Company's issued share capital.

 

Enquiries: 

 

Polarean Imaging plc 

www.polarean.com / www.polarean-ir.com 

Richard Hullihen, Chief Executive Officer 

Via Walbrook PR 

Richard Morgan, Chairman 

 

 

 

SP Angel Corporate Finance LLP 

Tel: +44 (0)20 3470 0470  

David Hignell / Soltan Tagiev (Corporate Finance) 

 

Vadim Alexandre / Rob Rees (Corporate Broking)

 

 

Walbrook PR 

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 

Anna Dunphy / Paul McManus 

Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Dr Jonathan Allis

2.

Reason for the notification

a)

Position/status:

Non-Executive Director

b)

Initial notification/Amendment:

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Polarean Imaging Plc

b)

LEI:

213800DGR2BHXJ36OL37

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

 

Ordinary shares of £0.00037

GB00BF3DT583

b)

Nature of the transaction:

Purchase of shares

c)

Price(s) and volume(s):

 

Price(s)

Volume(s)

29.9 pence

33,444

29.9 pence

33,444

29.9 pence

33,444

29.5 pence

33,898

29.5 pence

67,796

29.5 pence

50,847

29.5 pence

50,803

29.5 pence

33,898

 

d)

Aggregated information:

Aggregated volume:

Price:

 

Price(s)

Volume(s)

29.6 pence

337,574

 

 

 

e)

Date of the transaction:

20 January 2020

f)

Place of the transaction:

AIM, London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGZGZMVZGGGZM
Date   Source Headline
15th Feb 20237:00 amRNSInvestor presentation
13th Feb 20232:05 pmRNSSecond Price Monitoring Extn
13th Feb 20232:00 pmRNSPrice Monitoring Extension
13th Feb 202311:05 amRNSSecond Price Monitoring Extn
13th Feb 202311:00 amRNSPrice Monitoring Extension
13th Feb 20239:05 amRNSSecond Price Monitoring Extn
13th Feb 20239:00 amRNSPrice Monitoring Extension
13th Feb 20237:00 amRNSCompany Update
1st Feb 20234:40 pmRNSSecond Price Monitoring Extn
1st Feb 20234:35 pmRNSPrice Monitoring Extension
1st Feb 20234:25 pmRNSFDA grants New Chemical Entity designation
27th Jan 20237:00 amRNSBlock listing six monthly return
28th Dec 20229:05 amRNSSecond Price Monitoring Extn
28th Dec 20229:00 amRNSPrice Monitoring Extension
28th Dec 20227:00 amRNSFDA Approves XENOVIEW™ (Xe 129 hyperpolarized)
3rd Oct 202211:05 amRNSSecond Price Monitoring Extn
3rd Oct 202211:00 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSUpdate on New Drug Application
22nd Sep 20222:05 pmRNSSecond Price Monitoring Extn
22nd Sep 20222:00 pmRNSPrice Monitoring Extension
22nd Sep 202211:06 amRNSSecond Price Monitoring Extn
22nd Sep 202211:00 amRNSPrice Monitoring Extension
22nd Sep 20229:05 amRNSSecond Price Monitoring Extn
22nd Sep 20229:00 amRNSPrice Monitoring Extension
22nd Sep 20227:04 amRNSUpdate on New Drug Application
31st Aug 20227:00 amRNSHalf-year Report
26th Aug 20227:00 amRNSDirectorate appointment
4th Aug 20224:40 pmRNSSecond Price Monitoring Extn
4th Aug 20224:35 pmRNSPrice Monitoring Extension
28th Jul 20227:00 amRNSTotal voting rights and block listing return
8th Jul 20227:00 amRNSSystem delivery
29th Jun 20224:35 pmRNSResult of AGM
18th May 20227:00 amRNSFinal Results
11th May 20227:00 amRNSNotice of Results
11th May 20227:00 amRNSOxford research collaboration in long COVID
5th May 20227:00 amRNSDirectorate Change
29th Apr 20227:00 amRNSTotal Voting Rights
25th Apr 20227:00 amRNSNew system order
20th Apr 20227:00 amRNSNew Drug Application Resubmission update
14th Apr 20227:00 amRNSAppointment of Non-Executive Director
8th Apr 20227:00 amRNSExercise of Options and Total Voting Rights
31st Mar 20222:05 pmRNSSecond Price Monitoring Extn
31st Mar 20222:00 pmRNSPrice Monitoring Extension
31st Mar 202211:06 amRNSSecond Price Monitoring Extn
31st Mar 202211:00 amRNSPrice Monitoring Extension
31st Mar 20229:00 amRNSPrice Monitoring Extension
31st Mar 20227:00 amRNSNew Drug Application Resubmission
25th Feb 20227:00 amRNSTotal Voting Rights
14th Feb 20227:00 amRNSNew system order
28th Jan 20227:01 amRNSBlock Listing Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.